Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of calcium ion carrier in leucoderma treatment

A calcium ion carrier and vitiligo technology, applied in the field of medicine, can solve the problems of melanocytes' disturbance of calcium ion uptake and transport, and the inability to effectively correct vitiligo drugs and methods.

Active Publication Date: 2020-10-30
GUANGZHOU MEDICAL UNIV
View PDF10 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

During extensive research on the pathogenesis of vitiligo, the team of the present invention found that melanocytes in the affected areas of vitiligo have obstacles to the uptake and transport of calcium ions, and the existing drugs and methods for treating vitiligo cannot effectively correct this problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of calcium ion carrier in leucoderma treatment
  • Application of calcium ion carrier in leucoderma treatment
  • Application of calcium ion carrier in leucoderma treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Combined use of calcium ionophore Ⅰ and narrow-wave UVB in the treatment of vitiligo, and observe its effect on the synthesis of melanin in human melanocytes.

[0031] 1. Materials

[0032] 1.1 Cell line: Melanocytes around human vitiligo lesions, donated by the Dermatology Department of the First Affiliated Hospital of Kunming Medical University.

[0033] 1.2 Drug: calcium ionophore Ⅰ, CAS No.58801-34-6, specification: 50mg, brand: Sigma.

[0034] 1.3 Reagents and consumables: Melanocyte culture medium (Melm) was purchased from American Blue and White Company, fetal bovine serum was purchased from German PAN Company, trypsin was purchased from Shanghai Sangon Bioengineering Co., Ltd., dimethyl sulfoxide (DMSO) was purchased from The 3.5 cm cell culture plate was purchased from CORNING Company of the United States, the standard melanin was purchased from Sigma Company of the United States, and the BCA protein concentration determination kit was purchased from Beyontian...

Embodiment 2

[0044] Combined use of calcium ionophore Ⅳ and narrow-wave UVB to observe its effect on the synthesis of melanin in melanocytes. Except following difference, other is with embodiment 1.

[0045] 1 material

[0046] 1.2 Drug: calcium ionophore IV, CASNo.126572-74-5, specification: 50mg, brand: Sigma.

[0047] 2 test method

[0048] 2.2 Experimental grouping: The experiment was divided into 4 groups, namely negative control group (group A), UVB single action group (B group), calcium ionophore Ⅳ single action group (C group), UVB and calcium ionophore Ⅳ joint action group (Group D), the variables in the above 4 groups were consistent except for the relevant variables. In the negative control group, the cells in this group were not treated; in the UVB alone action group, the cells in this group were irradiated with a vitiligo UVB phototherapy instrument, and the irradiation dose was 9J / cm 2 , and then continue to culture for 12 hours; calcium ionophore Ⅳ alone action group, ad...

Embodiment 3

[0052] Combined use of calcium ionophore Ⅱ and dexamethasone to observe its effect on melanin synthesis by melanocytes. Except following difference, other is with embodiment 1.

[0053] 1 material

[0054] 1.2 Drug: calcium ionophore II, CAS No.74267-27-9, specification: 50mg, brand: Sigma. Dexamethasone, CAS No.50-02-2, specification: 100mg, brand: Sigma.

[0055] 2 Experimental methods

[0056] 2.2 Experimental grouping: The experiment was divided into 4 groups, namely negative control group (group A), dexamethasone alone action group (group B), calcium ionophore II alone action group (group C), dexamethasone and calcium ionophore In the Ⅱ joint action group (group D), the variables in the above 4 groups were consistent except for the relevant variables. In the negative control group, this group of cells was not treated; in the dexamethasone alone group, dexamethasone was added to the cell culture medium of this group to make the concentration of 1 μmol / L, and then conti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a calcium ion carrier and derivatives thereof in preparation of a medicine for treating leucoderma, and aims to solve the problem that melanocytes at an affected part of leucoderma have obstacles in uptake and transport of calcium ions. The calcium ion carrier is smeared on the affected part to increase the intake of calcium ions by melanocytes at the affected part so that the calcium steady state of the melanocytes is improved and recovered, a better intracellular calcium environment is provided for leucoderma treatment, the synthesis and transportation of melanin are promoted, and the defense of the melanocytes to free radicals and oxidative stress is enhanced. The application aims to serve as an adjuvant drug of the existing leucoderma treatmentdrug and method, and the existing treatment drug and method are assisted by improving the calcium environment in melanocytes of the affected part of leucoderma so that the treatment effect of the existing drug and method is improved, the treatment result is consolidated, and the disease recurrence rate is reduced.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of calcium ionophore in the treatment of vitiligo. Background technique [0002] Vitiligo is a common acquired depigmented skin and mucous membrane disease. Its clinical features are mainly manifested by the reduction or disappearance of epidermal melanocytes and the appearance of depigmented spots. The global incidence rate is about 0.5%. The number of patients in my country is more than 15 million, and the majority of the patients are young people. Its etiology is complex, the condition is repeated, and the exact pathogenesis has not yet been clarified. [0003] Effective treatment of vitiligo is still a difficult problem in clinical management. Existing therapeutic drugs and methods include topical external use, phototherapy or photochemical therapy, surgical treatment, systemic use of immunomodulatory drugs, systemic low-dose glucocorticoids, and dialectic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/23A61K41/00A61K31/16A61K31/573A61K31/65A61K31/436A61K31/423A61K31/665A61K31/341A61K31/58A61P17/00
CPCA61K45/00A61K31/23A61K41/0038A61K31/16A61K31/573A61K31/65A61K31/436A61K31/423A61K31/665A61K31/341A61K31/58A61K9/0014A61P17/00A61K2300/00
Inventor 王树陈文田维锋张文杰刘荆婧贺冬梅
Owner GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com